If you have been reading about Purity assay and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in water | Free peptide differs from the complex |
| Typical storage | approx. −20 °C, desiccated | Protect from light and moisture |
| Primary purity method | RP-HPLC with MS | Confirms peptide identity |
| Copper assay | ICP-MS or AAS | Measured separately from peptide purity |
| Main degradation routes | Metal loss, hydrolysis, oxidation | Rate depends on pH and matrix |
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Individuals receiving psychiatric treatment are commonly referred to as patients but may also be called clients, consumers, or service recipients. They may come under the care of a psychiatric physician or other psychiatric practitioners by various paths, the two most common being self-referral or referral by a primary care physician. Alternatively, a person may be referred by hospital medical staff, by court order, involuntary commitment, or, in countries such as the UK and Australia, by sectioning under a mental health law. A psychiatrist or medical provider evaluates people through a psychiatric assessment for their mental and physical condition. This usually involves interviewing the person and often obtaining information from other sources such as other health and social care professionals, relatives, associates, law enforcement personnel, emergency medical personnel, and psychiatric rating scales. A mental status examination is carried out, and a physical examination is usually performed to establish or exclude other illnesses that may be contributing to the alleged psychiatric problems. A physical examination may also serve to identify any signs of self-harm; this examination is often performed by someone other than the psychiatrist, especially if blood tests and medical imaging are performed. Like most medications, psychiatric medications can cause adverse effects in patients, and some require ongoing therapeutic drug monitoring, for instance full blood counts, serum drug levels, renal function, liver function or thyroid function.
== External links == Nonlinear Fracture Mechanics Notes by Prof. John Hutchinson, Harvard University Notes on Fracture of Thin Films and Multilayers by Prof. John Hutchinson, Harvard University Fracture Mechanics by Piet Schreurs, TU Eindhoven, The Netherlands
The US Food and Drug Administration (FDA) and Health Canada have approved pregabalin (an anticonvulsant) and duloxetine (a serotonin–norepinephrine reuptake inhibitor) for the management of fibromyalgia. The FDA also approved milnacipran (another serotonin–norepinephrine reuptake inhibitor), but the European Medicines Agency refused marketing authority. In 2025, the US Food and Drug Administration (FDA) approved TNX-102 SL, as Tonmya, for the management of fibromyalgia, making it the first new FDA-approved fibromyalgia therapy in over 15 years. (NDA 219428) A 2024 overview of Cochrane reviews concluded that the FDA-approved medications: duloxetine, milnacipran, or pregabalin were the only ones with evidence of efficacy. About 10% of patients with moderate or severe pain using them experienced a reduction of at least 50% in their pain. Another 2024 review found that currently available pharmacological options appeared to be limited in efficacy for FM. Fibromyalgia is often treated or managed with meds including amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine and sertraline. The length of time that medications take to be effective at reducing symptoms can vary. Any potential benefits from the antidepressant amitriptyline may take up to three months to take effect, and it may take between three and six months for duloxetine, milnacipran, and pregabalin to be effective at improving symptoms. Some medications have the potential to cause withdrawal symptoms when stopping, so gradual discontinuation may be warranted, particularly for antidepressants and pregabalin.
== Epidemiology == Accurate epidemiological data on the prevalence of cachexia is lacking due to changing diagnostic criteria and under-identification of people with the disorder. It is estimated that cachexia from any disease is estimated to affect more than 5 million people in the United States. The prevalence of cachexia is growing and estimated at 1% of the population. The prevalence is lower in Asia but due to the larger population, represents a similar burden. Cachexia is also a significant problem in South America and Africa. In people with cancer, prevalence of cachexia was previously reported to range from 11% to 71%. Recent updates show that 33%-51.8% of people with cancer develop cachexia, though estimates vary widely and may be unreliable due to absence of consensus guidelines for diagnosis, variability in cancer populations, and variability in timing of diagnosis. Specifically, the highest rates were seen in older populations as well as those with upper gastrointestinal, colorectal, and lung cancers, respectively. The prevalence increases in advanced cancer stages, affecting up to 80% of terminal cancer cases. The most frequent diseases causing cachexia in the United States are: 1) cancer, 2) chronic heart failure, 3) chronic kidney disease, 4) COPD. Cachexia contributes to significant loss of function and healthcare utilization. Estimates suggest that cachexia accounted for 177,640 hospital stays in 2016 in the United States. Cachexia is considered the immediate cause of death of many people with cancer, estimated between 22 and 40%.
-based regularization in a wavelet or other domain), such as via Ulf Grenander's Sieve estimator or via Bayes penalty methods or via I.J. Good's roughness method may yield superior performance to expectation-maximization-based methods which involve a Poisson likelihood function but do not involve such a prior. Attenuation correction: Attenuation occurs when photons emitted by the radiotracer inside the body are absorbed by intervening tissue between the detector and the emission of the photon. As different LORs must traverse different thicknesses of tissue, the photons are attenuated differentially. The result is that structures deep in the body are reconstructed as having falsely low tracer uptake. This must be corrected for when using quantitative PET imaging. One option for estimating attenuation coefficients is via a transmission scan, using a 68Ge rod source that is rotated around the patient Transmission scans directly measure attenuation values at 511 keV. With PET-CT scanners the 511 keV photon attenuation coefficients can be estimated using the Hounsfield units from the CT scan. Attenuation correction in PET-MRI scanners is more challenging, as the MRI images do not directly contain information on about the tissue attenuation coefficients, and the scanner bores are too narrow for a transmission scan.
Sources: en.wikipedia.org
Lymphadenopathy refers to one or more enlarged lymph nodes. Small groups or individually enlarged lymph nodes are generally reactive in response to infection or inflammation. This is called local lymphadenopathy. When many lymph nodes in different areas of the body are involved, this is called generalised lymphadenopathy. Generalised lymphadenopathy may be caused by infections such as infectious mononucleosis, tuberculosis and HIV, connective tissue diseases such as SLE and rheumatoid arthritis, and cancers, including both cancers of tissue within lymph nodes, discussed below, and metastasis of cancerous cells from other parts of the body, that have arrived via the lymphatic system.
Those who cannot tolerate ACE inhibitors may be treated with an angiotensin II receptor antagonist. Statin therapy has been shown to reduce mortality and subsequent cardiac events and should be commenced to lower LDL cholesterol. Other medications, such as ezetimibe, may also be added with this goal in mind. Aldosterone antagonists (spironolactone or eplerenone) may be used if there is evidence of left ventricular dysfunction after an MI, ideally after beginning treatment with an ACE inhibitor.
The three substrates of this enzyme are D-ribose, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are D-ribonic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-ribose:NADP+ 1-oxidoreductase. Other names in common use include D-ribose dehydrogenase (NADP+), NADP+-pentose-dehydrogenase, and ribose 1-dehydrogenase (NADP+).
==== Clinical trials ==== In terms of antimicrobial performance, studies report that the peptides found in DBHA can selectively kill microorganisms without significant toxicity to host cells. This is attributed to the presence of free protonated amines in G3KPCA, which interact with and disrupt negatively charged bacterial membranes, contributing to bactericidal activity. In vitro compatibility tests using mouse NIH-3T3 fibroblasts showed that DBHA is non-cytotoxic under the tested condition. DBHA has also been tested in more realistic conditions, including bleeding environments. When applied to porcine skin covered in blood, only minor differences were observed between wet and dry adhesion performance. It was also tested on tissues such as the stomach, heart, artery, and liver, where adhesion forces were measured. In rat incision models, DBHA was used in wound closure studies where closure was observed after seven days, in comparison to conventional sutures and commercial adhesives. Additional testing showed that after 24 hours in an adhesive conditioned medium, human dermal fibroblasts remained viable, indicating biocompatibility.
Sources: en.wikipedia.org
=== Production during the Manhattan Project === During World War II the U.S. government established the Manhattan Project, for developing an atomic bomb. The three primary research and production sites of the project were the plutonium production facility at what is now the Hanford Site, the uranium enrichment facilities at Oak Ridge, Tennessee, and the weapons research and design lab, now known as Los Alamos National Laboratory, LANL.
== Nomenclature == The terms chief cell and zymogenic cell are often used without the word "gastric" to name this type of cell. However, those terms can also be used to describe other cell types (for example, parathyroid chief cells). Chief cells are also known as peptic cells.
By the time Ferdinand Marcos' second term began, sugar had become a critical Philippine export, responsible for 27% of the county's total foreign exchange earnings. With international sugar prices rising rapidly through the early 1970s, Marcos decided to put domestic and international sugar trading under government control, first through the Philippine Exchange Co. (Philex), and later through the Philippine Sugar Commission (Philsucom) and its trading arm, the National Sugar Trading Corporation (NASUTRA), which were both controlled by Marcos crony Roberto Benedicto. However, the international price of sugar eventually crashed, dramatically hurting the livelihoods of poor farmers. The NASUTRA monopoly forced many sugar planters into bankruptcy or deep in debt. In 1984, over 190,000 sugar workers lost their livelihood, and about a million sacadas and their families in Negros suffered in what would later become known as the "Negros Famine."
== Synthesis == Routes to isoleucine are numerous. One common multistep procedure starts from 2-bromobutane and diethylmalonate. Synthetic isoleucine was first reported in 1905 by French chemists Bouveault and Locquin.
Pseudopeptidoglycan (also known as pseudomurein; PPG hereafter) is a major cell wall component of some Archaea that differs from bacterial peptidoglycan in chemical structure, but resembles bacterial peptidoglycan in function and physical structure. Pseudopeptidoglycan, in general, is only present in a few methanogenic archaea. The basic components are N-acetylglucosamine and N-acetyltalosaminuronic acid (bacterial peptidoglycan containing N-acetylmuramic acid instead), which are linked by β-1,3-glycosidic bonds. Lysozyme, a host defense mechanism present in human secretions (e.g. saliva and tears) breaks β-1,4-glycosidic bonds to degrade peptidoglycan. However, because pseudopeptidoglycan has β-1,3-glycosidic bonds, lysozyme is ineffective. It was thought from these large differences in cell wall chemistry that archaeal cell walls and bacterial cell walls have not evolved from a common ancestor but are only the result of a convergent evolution, but recent structural work has revealed deeper homology. No archaeal enzymes are known that cleave the β-1,3-glycosidic bonds in pseudopeptidoglycan, but it can be degraded by pseudomurein endoisopeptidase encoded by two prophages. The pseudomurein endoisopeptidases function by cleaving the peptide links between adjacent pseudopeptidoglycan strands.
Sources: en.wikipedia.org
The colour comes from electronic transitions in the coordinated copper(II) ion. Ligand field effects absorb part of the visible spectrum. A colourless or greenish sample may indicate degraded material.
Copper can be displaced by other metal ions, by strong chelating agents, or by low pH. Samples exposed to these conditions may contain a mixture of free peptide and complex. Analytical testing is the only reliable way to confirm the bound fraction.
Solution storage generally shortens shelf life compared with the dry powder. Hydrolysis and oxidation proceed faster in aqueous media. Where solutions are used, cold storage and short holding times reduce measurable change.
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.